Payment overview · 2025
General Payments
$1,297.40
52 reported records · 16 companies
Healthcare provider profile · identity verified
Arpana Edala, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LITTLE ROCK, AR · NPI 1265662969
Verified facts
What the public records show
CMS Open Payments records show Arpana Edala, MD received $1,297.40 in general payments during 2025 across 52 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 20.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1050 claims for Eliquis by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1050 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $267.06 | 20.6% | 8 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $167.72 | 12.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $166.51 | 12.8% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $163.26 | 12.6% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $131.62 | 10.1% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $116.37 | 9.0% | 6 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $68.40 | 5.3% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $67.09 | 5.2% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.36 | 1.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $22.78 | 1.8% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $21.24 | 1.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.81 | 1.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.69 | 1.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.64 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.15 | 1.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.70 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,297.40 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $430.32 | 18 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $167.72 | 3 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $141.09 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $116.37 | 6 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $68.40 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $67.95 | 4 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $67.09 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $63.67 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $48.92 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $25.42 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $25.42 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $25.36 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1050 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1050 | 96 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
194 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1050 | 96 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1303 | 243 |
| Eliquis | Apixaban | 1050 | 96 |
| Potassium Chloride | Potassium Chloride | 1013 | 184 |
| Furosemide | Furosemide | 891 | 161 |
| Donepezil Hcl | Donepezil Hcl | 826 | 153 |
| Memantine Hcl | Memantine Hcl | 723 | 130 |
| Gabapentin | Gabapentin | 642 | 117 |
| Pantoprazole Sodium | Pantoprazole Sodium | 557 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 523 | 137 |
| Divalproex Sodium | Divalproex Sodium | 501 | 107 |
| Escitalopram Oxalate | Escitalopram Oxalate | 474 | 133 |
| Mirtazapine | Mirtazapine | 459 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 458 | 101 |
| Losartan Potassium | Losartan Potassium | 415 | 91 |
| Metformin Hcl | Metformin Hcl | 403 | 70 |
| Trazodone Hcl | Trazodone Hcl | 403 | 109 |
| Tamsulosin Hcl | Tamsulosin Hcl | 399 | 66 |
| Lisinopril | Lisinopril | 392 | 84 |
| Sertraline Hcl | Sertraline Hcl | 391 | 86 |
| Clopidogrel | Clopidogrel Bisulfate | 347 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 333 | 70 |
| Metoprolol Tartrate | Metoprolol Tartrate | 333 | 63 |
| Carvedilol | Carvedilol | 298 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 248 | 58 |
| Baclofen | Baclofen | 232 | 42 |
| Meloxicam | Meloxicam | 210 | 53 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 204 | 42 |
| Xarelto | Rivaroxaban | 194 | 16 |
| Buspirone Hcl | Buspirone Hcl | 174 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 163 | 48 |
| Myrbetriq | Mirabegron | 160 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 42 |
| Entresto | Sacubitril/Valsartan | 157 | 12 |
| Simvastatin | Simvastatin | 151 | 22 |
| Omeprazole | Omeprazole | 149 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 38 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 144 | 25 |
| Sucralfate | Sucralfate | 144 | 25 |
| Bumetanide | Bumetanide | 143 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 141 | 27 |
| Montelukast Sodium | Montelukast Sodium | 130 | 23 |
| Gemtesa | Vibegron | 129 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 123 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 123 | 26 |
| Prednisone | Prednisone | 122 | 28 |
| Spironolactone | Spironolactone | 122 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 121 | 47 |
| Nifedipine Er | Nifedipine | 121 | 19 |
| Levetiracetam | Levetiracetam | 118 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 118 | 39 |
| Glipizide | Glipizide | 115 | 20 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 115 | 51 |
| Allopurinol | Allopurinol | 114 | 27 |
| Midodrine Hcl | Midodrine Hcl | 111 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 108 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 103 | 53 |
| Tramadol Hcl | Tramadol Hcl | 101 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 33 |
| Ondansetron Hcl | Ondansetron Hcl | 100 | 62 |
| Finasteride | Finasteride | 97 | 14 |
| Torsemide | Torsemide | 96 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 95 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 92 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 86 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 81 | 14 |
| Alendronate Sodium | Alendronate Sodium | 79 | 27 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 77 | 75 |
| Humalog | Insulin Lispro | 76 | 17 |
| Insulin Lispro | Insulin Lispro | 73 | 28 |
| Januvia | Sitagliptin Phosphate | 73 | suppressed |
| Latanoprost | Latanoprost | 73 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 68 | suppressed |
| Olanzapine | Olanzapine | 67 | suppressed |
| Nyamyc | Nystatin | 63 | 33 |
| Amiodarone Hcl | Amiodarone Hcl | 61 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 53 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 17 |
| Celecoxib | Celecoxib | 59 | 12 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 58 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 53 | suppressed |
| Topiramate | Topiramate | 52 | suppressed |
| Ezetimibe | Ezetimibe | 51 | suppressed |
| Fluconazole | Fluconazole | 48 | 28 |
| Ipratropium Bromide | Ipratropium Bromide | 48 | 24 |
| Nystatin | Nystatin | 48 | 32 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 48 | suppressed |
| Tresiba | Insulin Degludec | 46 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 26 |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | suppressed |
| Bupropion Xl | Bupropion Hcl | 43 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Atenolol | Atenolol | 41 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 41 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 40 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | suppressed |
| Calcium Acetate | Calcium Acetate | 40 | suppressed |
| Lactulose | Lactulose | 40 | suppressed |
| Ozempic | Semaglutide | 40 | 15 |
| Lidocaine Hcl | Lidocaine Hcl | 39 | 34 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 38 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 37 | suppressed |
| Letrozole | Letrozole | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 36 |
| Mirabegron Er | Mirabegron | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 22 |
| Irbesartan | Irbesartan | 35 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 35 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Haloperidol | Haloperidol | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 16 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 32 | 16 |
| Lorazepam | Lorazepam | 32 | 14 |
| Risperidone | Risperidone | 32 | 11 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 31 | 19 |
| Digoxin | Digoxin | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Permethrin | Permethrin | 31 | 20 |
| Sevelamer Carbonate | Sevelamer Carbonate | 31 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 29 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 28 | suppressed |
| Clonidine | Clonidine | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 27 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | suppressed |
| Methimazole | Methimazole | 27 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 23 |
| Trimethoprim | Trimethoprim | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Brilinta | Ticagrelor | 25 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 25 | 23 |
| Cephalexin | Cephalexin | 25 | 23 |
| Clonidine Hcl | Clonidine Hcl | 25 | 15 |
| Famotidine | Famotidine | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 17 |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 13 |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 22 |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Eplerenone | Eplerenone | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | 12 |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 19 |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Novolog | Insulin Aspart | 20 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 20 | 19 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 20 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 19 | 11 |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Minoxidil | Minoxidil | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 16 |
| Clonazepam | Clonazepam | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Methadone Hcl | Methadone Hcl | 16 | suppressed |
| Pentoxifylline | Pentoxifylline | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Zonisamide | Zonisamide | 15 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 14 | 14 |
| Nystop | Nystatin | 14 | 13 |
| Ondansetron Odt | Ondansetron | 14 | 11 |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Insulin Aspart | Insulin Aspart | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Fingolimod | Fingolimod Hcl | 12 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 12 | 12 |
| Morphine Sulfate | Morphine Sulfate | 12 | 11 |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Admelog | Insulin Lispro | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Ertapenem | Ertapenem Sodium | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,297.40 · 52 records | Otsuka America Pharmaceutical, Inc. | AIRSUPRA, AUSTEDO XR, CAPVAXIVE, COBENFY, Cologuard Collection Kit, ELIQUIS, KISUNLA, Kerendia, Leqembi, MOUNJARO, NUPLAZID, NURTEC ODT, OTEZLA, REPATHA, REXULTI, SPRAVATO, TAVNEOS, VOWST, WATCHMAN Access System, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error